A 90-day study was conducted to compare the effects of dietary administration of a food-grade white oil in female Fischer-344 (F-344) and Sprague-Dawley-derived (CRL:CD) rats. Animals were fed a low viscosity (15 mm 2 /sec at 40&deg;C) paraffinic white oil (designated as P 15[H]) at 0, 0.2, or 2.0% of the diet for 30, 61, or 92 days. There were no significant adverse clinical observations or unscheduled deaths. In the F-344 rats, occasional treatment-related changes were seen in hematology and clinical chemistry parameters. At necropsy, mesenteric lymph nodes were enlarged, and there was an increase in absolute and relative liver, mesenteric lymph node, and spleen weights as compared to controls. Histopathologic effects included hepatic and mesenteric lymph node microgranulomas and mesenteric lymph node histiocytosis. In CRL:CD rats, the only effects noted were accumulations of chronic inflammatory cells in the liver at the high dose only, without the formation of discrete microgranulomas. A dose-related increase in mineral hydrocarbon (MHC) material in the liver and mesenteric lymph nodes was observed in both F-344 and CRL:CD rats. Although increased, liver MHC content was significantly less (approximately 50%) in CRL:CD rats than the levels detected in the F-344 rats. Mesenteric lymph node MHC levels did not differ significantly between the strains. This study demonstrated strain differences among rats in histopathologic effects of white oil, with the CRL:CD rat essentially showing no response compared to the F-344 rat. The differences in the pathologic responses between the 2 strains appears to result from the higher MHC tissue content and a greater sensitivity of the F-344 rat to the presence of the MHC material.
INTRODUCTION
White mineral oils are complex mixtures of saturated hydrocarbons derived from petroleum by distillation and purification to remove undesirable aromatic compounds and other impurities (4) . They are comprised of predominantly 2 hydrocarbon types: paraffinics, which are branched chain alkanes, and naphthenics, which are alkanes containing 1 or more saturated cyclic structures. During manufacture, nearly all linear alkanes, which are used to produce paraffin waxes, are removed. Food-grade mineral hydrocarbons (MHCs) and medicinal white oils are used in food processing as binders, lubricants, or coating agents. Liquid paraffin is also used orally for its cathartic properties (8) . Baldwin et al (2) and CONCAWE (5) have reported that certain white mineral oils elicit granulomas in the liver and mesenteric lymph nodes of Fischer-344 (F-344) rats following 90-day exposure to high dietary concentrations (up to 2.0% in the diet). Increased levels of MHC material were detected in affected tissues. Effects were generally more severe in female rats than in males and were inversely correlated with the average molecular weight of the MHC product. These findings had not been observed in previous subchronic and chronic feeding studies with similar products conducted in different species and rat strains, including dogs, Long-Evans rats, and Sprague-Dawley rats (1, 3, 11) . White mineral oils have also been used as a vehicle control in gavage studies on other petroleum hydrocarbons in Sprague-Dawley rats, without effect (1, 10) . However, no direct comparison studies on white mineral oils in different rodent strains have been reported.
The objectives of this studv were to reproduce the liver and mesenteric lymph node histopathologic changes in female F-344 rats as previously described (2, 5) and to characterize the strain differences in tissue MHC uptake and subsequent responses following exposure to a representative food-grade white oil for up to 92 days. Female Sprague-Dawley (CRL: CD) rats were selected for comparison purposes because they are a common strain of laboratory rat and had been used in previous studies on white mineral oils.
MATERIALS AND METHODS
Test Article. The test white oil, P I S(H), was a clear, colorless liquid refined by hydrogenation from parafhnic crude (Esso Societe Anonyme Francaise, Mont-Saint-Aignan, France). It had a specific gravity of 0.851 at 1 S°C and a viscosity of 14.80 mm'-/ sec at 40°C. The purity of the bulk sample conformed to the standards set forth by the European Pharmacopoeia. Alpha-tocopherol ( formed on all animals. An extensive list of tissues and organs, including gross lesions, were removed and preserved in 10% neutral-buffered formalin. The heart, kidneys, liver, ovaries, and spleen were weighed prior to fixation. The mesenteric lymph nodes (MLNs) were allowed to fix prior to weighing.
The liver, MLNs, and all gross lesions from all animals were routinely processed, sectioned, stained (hematoxylin and eosin), and examined microscopically. Samples of liver. MLNs. spleen, and kidney were removed and stored at -~0°C for MHC analsis. MHC Analysis. Feed and homogenized tissue samples were analyzed for MHC by extraction with Freon 1 12 (1,1,-4-trichloro-triflu-oroethane) followed by a cleanup using a partially deactivated norisil column (13) . The eluants were analyzed against known test article standards for MHC on a Fourier Transform Infrared Spectrophotometer (Nicolet Model #205, 10 mm quartz cell). The in- frared absorbance was measured in the C-H stretching region (X = 2,930 cm-'). Homogeneity, stability, and concentration verification in dietary preparations were also performed using the same procedure. Statistical Analysis. Statistical evaluation was conducted using parametric and nonparametric procedures at both the 5% and 1 % level of significance. For the parametric procedures, a 1-way analysis of variance using the F distribution to assess significance was used (12) . If significant differences among the means were indicated, Dunnett's test was utilized (7) . In addition to the analysis of variance, a standard regression analysis for linear response in the dose groups was performed. For the nonparametric procedures, the Kruskal-Wallis test was applied (9) . If significant differences were noted, Dunn's summed rank test was used to determine which groups differed from the control (9) . Also, Jonckheere's test for monotonic trend in the dose-response was applied. The statistical t-test was also used to compare the control and 2.0% dose group F-344 rat data at the interim sacrifices on day 30 and day 61 (6) . A statistical evaluation for the presence of extreme observations was conducted (12) . If the presence of an outlier was determined, it was rejected at the 5% level of significance.
RESULTS

Clinical Observations
There were no clinical signs considered related to treatment with P 15(H), and there were no unscheduled deaths. The F-344 rats in the 2.0% dosage group showed a transient decrease in body weight gain on day 21 only. Otherwise, there were no differences in mean body weight between the treated and control rats of either strain. There were no significant changes in mean food consumption between treated and control rats of either strain.
Clinical Pathology
In F-344 rats, the only significant hematological change was a neutrophilic leukocytosis expressed as percentage of total white blood cell (WBC) counts. At day 30. the 2.0% dosage group showed a slight leukocytosis (normal differential) as compared to controls. At day 61, the total WBC count in the 2.0% dosage group was significantly elevated over controls, and by 92 days the neutrophilic leukocytosis occurred in a dose-related pattern (Table II) .
A few minor changes in the clinical chemistry endpoints were seen in the F-344 rats (Table II) . Gamma-glutamyl transpeptidase activity was increased in both the 0.2% ( 1.7-fold) and 2.0% (1.5fold) dosage groups, and cholesterol levels were marginally increased (1.3-fold) in the 0.2% dose group compared to controls at study termination (day 92). There was a statistically significant decrease (1.4fold) in the triglyceride levels of the 2.0% dose group at day 92 only. In addition, slight transient increases in mean glucose, sodium, chloride, calcium, phosphorous, total protein, albumin, alanine aminotransferase, and aspartate aminotransferase were seen at the 30-day interval (data not shown) but not at the 61or 92-day interval. All of the clinical chemistry changes were marginal, did not occur in a dose-related manner, were within normal levels seen in historical control animals, and were not considered clinically significant.
There were no statistically significant differences in hematology or serum chemistry parameters between treated and control CRL:CD rats at the scheduled terminal sacrifice.
Necropsy
Treatment-related organ weight effects were observed in the liver and MLNs in the F-344 rats only.
A statistically significant increase in both the absolute ( 1.2-fold) and relative ( 1.3-fold) mean liver weight values was observed in the 2.0% dose group F-344 rats over controls at all intervals (Fig. 1 a) . At study termination, the 0.2% dose group exhibited a statistically significant increase in the absolute ( 1.1fold) and relative (1.l-fold) liver weight. Similarly, there was a statistically significant increase in the mean absolute (1.4 to 3.7-fold) and relative (1.4 to 3.8-fold) MLN weight of the 2.0% dose group F-344 rats compared to controls at all intervals (Fig. 1 b) . There were no statistically significant differences in the mean absolute organ weight or relative organ 
Tissue MHC Analyses
There was a dose-and strain-related increase in the levels ofMHC in the liver and MLNs from both rat strains (Table III) . Expressed as micrograms per gram of tissue following correction for control values, tissue MHC was greatest in the liver. Although both strains showed increases in the levels of hepatic MHC (jig MHC/g tissue), F-344 rats had 2.2-and 2.0-fold greater amounts in the 0.2% and 2.0% dosage groups, respectively, than CRL:CD rats.
There was a dose-related increase in the levels of MHC in the MLNs in both rat strains (Table III) . This trend was more apparent when expressed as total MHC content than when expressed as jig MHC/g tissue. Histopathologh
Treatment-related microscopic changes were observed in the liver and'or MLNs of the F-344 rats of the 0.2% (day 92) and 2.0% (days 30, 61, and 92) dosage groups. The treatment-related effect in the livers of the F-344 rats was characterized by an increased incidence of microgranuloma formation (Fig. 2) . The microgranulomas were not present on day 30, but they were present in greater than 80% of the animals by day 61 in the 2.0% dose group. By day 92, microgranulomas were also observed in the 0.2% dose group.
The microgranulomas were present primarily around the central veins and increased in both size and number at the high dose (Fig. 3a, b) . They typically contained a central core of epithelioid macrophages often surrounded by a rim of mononuclear cells, usually lymphocytes. Occasional microgranuloma exhibited central necrosis and/or the presence of Langhan's type giant cells. The incidence and severity were both dose-related and temporally related as the appearance of hepatic microgranulomas occurred at 61 days (2.0% dosage group) and was observed at the 0.2% and 2.0% levels at 92 days. A no=effect level for hepatic microgranuloma formation in F-344 rats was not identified in this study. were not present at the day 30 interval. In F-344 rats. the incidence was > 80% in the 2.0°~6 dosage group at 6 days and 45 and 95% in the 0.2% and 2.0°~o groups at day 92, respectively. Discrete microgranuloma were not observed in the livers of CRL:CD rats. ND = not determined. 0 Microscopic examination of the liver from the CRL:CD rats revealed a slightly increased incidence of minimal multifocal chronic inflammation in the 2.0% dose group at the day 92 terminal sacrifice. In contrast to the F-344 rats. discrete microgranulomas were not observ-ed in either dose group (0.2% or 2.0%) of CRL:CD rats.
In the MLNs of F-344 rats, histiocytosis occurred in the 2.0% dose group at 30 days (Fig. 4a ) and was characterized by increased numbers of histiocytictype macrophages throughout the sinusoids, especially the subcapsular sinus. Several lymph nodes from the F-344 rats had focal accumulations of eosinophils present. Microgranulomas were observed at 61 and 92 days in the 2.0% and also in the 0.2% dose groups at 92 days (Fig. 4b ). Affected MLNs contained focal or coalescing microgranulomas located throughout the node but frequently in the outer cortex adjacent to the subcapsular sinus (Fig. 5 ). As shown in Fig. 5a and b, the incidence and severity of the microgranulomas were increased in a doserelated manner. A no-effect level (in F-344 rats) for the MLNs was not identified under the conditions of this study. No histopathologic changes were seen in the MLNs of CRL:CD rats.
DISCUSSION
Numerous subchronic and chronic toxicity studies on mineral oils and other highly refined hydrocarbons showed no evidence of toxicity in several animal species, including dogs, rabbits, guinea pigs, and Sprague-Dawley-derived and Long-Evans rats (1, 3, 10, 11) . In contrast to these results, recent white oil studies in F-344 rats found clinical and anatomical pathologic changes that were generally dose-related and compound-dependent (2, 5) . Using a food-grade white mineral oil previously tested by CONCAWE (5), we were able to reproduce the changes in the F-344 rat as described and demonstrate the relative unresponsiveness of the CRL:CD rat under similar exposure conditions. In the present study, the findings in the F-344 rats paralleled those of Baldwin et al (2) and CONCAWE (5) with a few exceptions. Leukocytosis was observed in this study as well as the previous studies. However, both Baldwin et al (2) and CONCAWE (5) noted a slight hypochromic microcytic anemia   FIG. 4. -a~ Incidence of MLN histiocytosis in female CRL:CD and F-344 rats fed 0.2% or 2.0% P 15(H) white oil for 92 days. Over the course of the study, the diffuse histiocytic reaction progressed to discrete microgranuloma formation. b) MLN microgranulomas were not present at the 30-day interval. In F-344 rats, the incidence was 100% in the 2.0% dosage group after 61 days and 80 and 90% in the 0.2% and 2.0% dosage groups at day 92, respectively. No significant histopathologic changes were noted in the MLNs from CRL:CD rats. ND = not determined.
following 90 days of exposure, which was not observed in this study.
The observed changes in serum chemistry in F-344 rats included increases in cholesterol and ~y-glutarnyl transpeptidase and decreases in triglycerides. Small transient increases in both aspartate aminotransferase and alanine aminotransferase were noted in the 2.0% dose group at the day 30 interval. However, the values returned to control levels by day 61 and remained unchanged at the day 92 terminal sacrifice. Previous studies in F-344 rats also revealed similar trends in the liver-specific enzymes, such as alanine aminotransferase, which may indicate hepatic changes (2, 5) . The variations were generally small in magnitude and occurred predominantly in the 2.0% dose group, although various differences as compared to controls were also observed at the 0.2% dose level. The sporadic changes in serum chemistry noted in this study may demonstrate that these serum enzymes were not a sensitive indicator of the resulting pathology. Serum cholesterol, albumin, and/or total protein levels were sporadically increased over control values in the present study, whereas Baldwin et al (2) reported decreases in these parameters. The difference in these findings may indicate that they are not treatment-related and may be incidental. Increases in serum albumin and total protein may be the result of hypovolemia or slight dehydration.
Consistent with previous studies, treatment-related organ weight changes were observed in F-344 rats in the MLNs, liver, and spleen (2, 5) . In contrast to Baldwin et al (2) and CONCAWE (5) , no kidney weight change was observed in the present study.
The pathologic changes in the liver (microgranuloma) and MLNs (microgranuloma, histiocytosis) observed in this study were also consistent with those observed in previous studies in F-344 rats (2, 5) . In this study, as in previous studies, significant amounts of MHC material were found in the liver and MLNs, with smaller amounts in the spleen and kidneys (2, 5) . MHC levels in the liver of the 0.2% F-344 dose group were similar in magnitude to the 2.0% CRL: CD dose group, yet only the F-344 rats exhibited microgranuloma. MHC levels in the MLNs were similar in the F-344 and CRL:CD rats. However, the pathology (i.e., microgranuloma formation) occurred only in the F-344 rats. This suggests that the F-344 rat also has a greater response to a given tissue level of MHC.
Given the marked species and strain differences in response to white oils, the relevance of effects seen in F-344 rats for human health risk assessment is questionable. In humans, prolonged and repeated exposure to white mineral oils have been presumed to result in their presence in tissues, including the liver, spleen, and MLNs (1, 14) . However, no toxic responses or clinically significant effects have been ascribed to their presence (14) . Similarly, although MHC material was present in tissues of CRL:CD rats, no treatment-related adverse effects were observed. These findings are consistent with studies conducted on similar MHC materials in other species ( 1, 3, 10, 11) . The species/strain differences in these and other reported studies and the historical safe human exposure to white oils should be collectively considered in assessing the relevance of the F-344 rat effects to human health.
In conclusion, there are not only species differences in the effect of MHCs on the liver and lymph nodes, but this study demonstrated strain differences among rats, with the CRL:CD rat showing essentially no response compared to the F-344 rat.
Consistent with results from previous studies conducted in F-344 rats, dietary administration of P 15(H) white mineral oil resulted in elevated levels of MHC in selected organs and histopathologic evidence of an inflammatory response. The CRL:CD rats, on the other hand, had less MHC in tissues, and treatment-related findings were limited to minimal multifocal chronic inflammation in the 2.0% dose group. F-344 rats not only had greater levels of MHC material in several tissues but were also more sensitive to the presence of that material than the CRL:CD rats. Further research is needed to determine whether the observed species and strain differences in response are due to pharmacokinetics and/or pharmacodynamic mechanisms and to assess the potential relevance of these finding to human health.
